SEC Form 4 · accession 0001654954-17-008691
Acer Therapeutics Inc. · ACER
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Aselage
Director
Period of report
Sep 19, 2017
Accepted (ET)
Sep 21, 2017 · 5:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001069308
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 19, 2017 | J | 11,905 | — | A | 11,905 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonqualified Stock Option (right to buy)F2,F3 | $2.55 | Sep 19, 2017 | J | 21,000 | A | — | Oct 19, 2025 | Common Stock | 21,000 | 21,000 | D |
Explanation of responses
- F1Received in connection with the Issuer's business combination (the "Merger") with what was then known as "Acer Therapeutics Inc." ("Private Acer") in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated June 30, 2017 among the Issuer, Opexa Merger Sub, Inc. and Private Acer, in exchange for 11,905 shares of common stock of Private Acer.
- F2Received in connection with the Merger in exchange for an option to acquire 21,000 shares of common stock of Private Acer.
- F3Option vests in eight equal quarterly installments beginning on October 19, 2015.